Kaixin Pharmaceuticals Acquires CASI Pharmaceuticals Assets for $20 Million
On May 12, Kaixin Pharmaceuticals, Inc. announced that it entered into an agreement to acquire assets of CASI Pharmaceuticals. The purchase price is $20 million, which shall include assumption of up to $20 million of indebtedness of CASI. CASI Pharmaceuticals is a Cayman Island incorporated biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. Kaixin Pharmaceuticals is a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of CASI Pharmaceuticals and two direct subsidiaries of CASI Pharmaceuticals in China. Under the terms of the agreement, Kaixin... Read More »
Concentra Acquires Kronos
On May 2, Concentra Biosciences reported that it acquired Kronos Bio, Inc. for $34.7 million. As of April 30, 2025, there were 60,969,214 Kronos common stock shares. At a price of $0.57 per share, the total purchase price is nearly $34.8 million. Kronos Bio is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Kronos Bio has a research facility in East Cambridge, Massachusetts. Concentra Biosciences is owned by Tang Capital Partners, a life sciences-focused investment company. The company was founded in 1979. Concentra will acquire Kronos’... Read More »
Merck KGaA, Darmstadt, Germany Buys SpringWorks Therapeutics
Merck KGaA, Darmstadt, Germany announced that it is acquiring SpringWorks Therapeutics, a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The transaction is expected to close in the second half of 2025. SpringWorks is developed and commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors and GOMEKLI™ (mirdametinib) as the first and only FDA-approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas. It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid... Read More »
Gate Neurosciences Acquires Boost Neuroscience
Gate Neurosciences announced on February 18 that it acquired Boost Neuroscience for an undisclosed price. The seller was Catalio Capital Management, an investment management firm based in New York City. Boost Neuroscience is a “stealth” biotechnology company focused on the discovery and development of novel synaptogenic targets and therapies. It was spun out of the Stanford University lab of Dr. Thomas Südhof, MD. The company, while owned by Catalio Capital Management, developed a proprietary platform that models neuronal network circuits using human iPSC cells to gain unparalleled insights into how molecules impact neuronal networks, synaptogenesis, synaptic function and... Read More »
Takara Bio USA Holdings Acquires Curio Bioscience
On January 15, Takara Bio USA Holdings Inc., a wholly owned subsidiary of Takara Bio Inc., announced that it acquired Curio Bioscience. Curio Bioscience is a biotechnology company that is advancing a new generation of high-precision tools for the life sciences industry. The company has developed spatial biology capabilities to map the whole transcriptome at high resolution using existing sequencing workflows and instrumentation. Takara Bio USA Holdings Inc. manufactures and distributes kits, reagents and instruments for the life sciences, including next-generation sequencing, gene delivery, genome editing, stem cell research, nucleic acid and protein purification and... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
